Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207,440,936
-
Total 13F shares
-
30,504,107
-
Share change
-
-498,824
-
Total reported value
-
$1,133,787,977
-
Put/Call ratio
-
66%
-
Price per share
-
$37.17
-
Number of holders
-
160
-
Value change
-
-$33,669,118
-
Number of buys
-
61
-
Number of sells
-
85
Institutional Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q3 2020
As of 30 Sep 2020,
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) was held by
160 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
30,504,107 shares.
The largest 10 holders included
Bellevue Group AG, Meditor Group Ltd, WASATCH ADVISORS INC, VANGUARD GROUP INC, Pentwater Capital Management LP, BlackRock Inc., STATE STREET CORP, MARSHALL WACE, LLP, BOXER CAPITAL, LLC, and PLATINUM INVESTMENT MANAGEMENT LTD.
This page lists
162
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.